Systematic review of 23 studies in HR+/HER2- breast cancer: CDK4/6 inhibitors plus endocrine therapy vs endocrine therapy alone raised grade 3/4 QTc prolongation risk (RR 1.83, driven by ribociclib) and VTE risk (RR 2.57, highest with abemaciclib).
Meta-analysisn = 23 studies
Hoo et al. Risk of QTc prolongation, and major cardiovascular adverse events associated with CDK4/6 inhibitors in hormone receptor-positive HER2-negative breast cancer - A systematic review and meta-analysis